Efficacy and Safety of a Low-Flow Extracorporeal Carbon Dioxide Removal System in Acute Respiratory Failure, a Pilot Study in China

Abstract

<b><i>Background:</i></b> Low-flow extracorporeal carbon dioxide removal (LF-ECCO<sub>2</sub>R) has the potential to play an important role in the management of adults with acute respiratory failure. However, it has never been tested in China. The study aimed at exploring the safety and efficacy on LF-ECCO<sub>2</sub>R for acute respiratory failure in a Chinese tertiary intensive care unit (ICU). <b><i>Materials and Methods:</i></b> We performed a retrospective case note review of patients admitted to our tertiary regional ICU and commenced on LF-ECCO<sub>2</sub>R from June 2020 to September 2021. The LF-ECCO<sub>2</sub>R device we used was ProLUNG® system (Estor S.p.A., Milan, Italy). The device employed a nonporous poly-4-methyl-1-pentene membrane lung with a surface area of 1.81 m<sup>2</sup> and run at an extracorporeal blood flow between 100 and 450 mL/min. Demographic and physiologic data (including ventilation parameters and arterial blood gases) as well as the outcome of LF-ECCO<sub>2</sub>R treatment were recorded. <b><i>Results:</i></b> A total of 12 cases were included. A statistically significant reduction in respiratory rate, driving pressure, PaCO<sub>2</sub>, and blood lactate was observed. In addition, there was a statistically significant improvement in pH and PaO<sub>2</sub>/FiO<sub>2</sub>. Six out of 12 patients (50%) were discharged alive from ICU. Three complications related to LF-ECCO<sub>2</sub>R were reported, none resulting in serious adverse outcomes. <b><i>Conclusion:</i></b> Our clinical series indicated that LF-ECCO<sub>2</sub>R seemed to be safely applied in patients with acute respiratory failure. The efficacy of CO<sub>2</sub> removal as well as the improved respiratory parameters was also observed. However, large-scale randomized clinical trials are needed to confirm the effects.